Eiger BioPharmaceuticals, Inc. (EIGRQ)
| Market Cap | 12.59M |
| Revenue (ttm) | 15.77M |
| Net Income (ttm) | -74.96M |
| Shares Out | 1.48M |
| EPS (ttm) | -50.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 427 |
| Open | 8.35 |
| Previous Close | 8.35 |
| Day's Range | 8.35 - 8.50 |
| 52-Week Range | 1.10 - 16.00 |
| Beta | 2.78 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 1, 2024 |
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that... [Read more]
Financial Performance
In 2023, Eiger BioPharmaceuticals's revenue was $15.77 million, an increase of 16.98% compared to the previous year's $13.48 million. Losses were -$74.96 million, -22.54% less than in 2022.
Financial StatementsNews
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.